ProCE Banner Series

Taking Control in Moderate to Severe Atopic Dermatitis: Expert Guidance for Advancing Treatment With Biologic Therapies

Hear expert guidance to incorporate more routine assessments of disease activity and response to treatment to inform decisions about advancing therapy and to recognize all patients who would benefit from approved biologic therapies. In addition, gain knowledge of the distinct clinical characteristics and recent safety and efficacy data for available biologic therapies to competently navigate treatment decisions for patients with moderate to severe atopic dermatitis.

  AAPA
  | AMA
  | ANCC
Who Should Attend

This education is intended for dermatologists, allergists/immunologists, nurse practitioners, and physician associates practicing in dermatology who manage patients with moderate to severe atopic dermatitis.

All Events

Taking Control in Moderate to Severe Atopic Dermatitis: Expert Guidance for Advancing Treatment With Biologic Therapies

Upcoming Events

April

09

2025

6:00 PM - 7:00 PM Pacific Time (PT)

Virtual

April

30

2025

8:00 PM - 9:00 PM Eastern Time (ET)

Virtual

Topics

Atopic Dermatitis

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this educational program is to improve learners’ knowledge and competence managing advanced therapy for patients with moderate to severe atopic dermatitis.

Target Audience
This education is intended for dermatologists, allergists/immunologists, nurse practitioners, and physician associates practicing in dermatology who manage patients with moderate to severe atopic dermatitis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate therapeutic response and treatment advancement needs of patients with moderate to severe AD

  • Classify clinical characteristics of patients who would benefit from approved biologic therapies for moderate to severe AD

  • Appraise available safety and efficacy evidence and distinct clinical profiles of available biologic therapies targeting IL-4/IL-13 and IL-13 for patients with moderate to severe AD

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit ACCME | CME Passport to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC

This activity is supported by an educational grant from Lilly.